Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply

Georgios Kokkotis; Konstantina Kitsou; Giorgos Bamias

doi:10.1111/apt.16904

Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply

Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.

Authors

Georgios Kokkotis¹, Konstantina Kitsou², Giorgos Bamias¹

Affiliations

¹ GI Unit, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
² Immunobiology and Vaccinology Research Lab, First Department of Paediatrics, "Aghia Sophia" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

This article is linked to Kokkotis et al papers. To view these articles, visit https://doi.org/10.1111/apt.16717 and https://doi.org/10.1111/apt.16872

Publication types

Letter
Comment

MeSH terms

COVID-19*
Crohn Disease*
Humans
Inflammatory Bowel Diseases*
Tumor Necrosis Factor Inhibitors

Substances

Tumor Necrosis Factor Inhibitors